Abstract

The era of personalized medicine has arrived, but not in the way that many predicted. Rather than emerging as clinical tools derived from years of biomedical research that characterized the accuracy and clinical usefulness of genetic markers of increased disease risk, the first publicly available applications of whole-genome technologies are being developed primarily in the private sphere, by companies that market testing services directly to consumers through the Internet.